| KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS C Ambrogio, J Köhler, ZW Zhou, H Wang, R Paranal, J Li, M Capelletti, ... Cell 172 (4), 857-868. e15, 2018 | 265 | 2018 |
| Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors T Kosaka, J Tanizaki, RM Paranal, H Endoh, C Lydon, M Capelletti, ... Cancer research 77 (10), 2712-2721, 2017 | 139 | 2017 |
| Potent and selective covalent quinazoline inhibitors of KRAS G12C M Zeng, J Lu, L Li, F Feru, C Quan, TW Gero, SB Ficarro, Y Xiong, ... Cell chemical biology 24 (8), 1005-1016. e3, 2017 | 138 | 2017 |
| Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives S Mowafy, A Galanis, ZM Doctor, RM Paranal, DS Lasheen, NA Farag, ... Bioorganic & medicinal chemistry 24 (16), 3501-3512, 2016 | 46 | 2016 |
| Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non–Small Cell Lung Cancer B Ricciuti, J Son, JJ Okoro, A Mira, E Patrucco, Y Eum, X Wang, R Paranal, ... Clinical Cancer Research 28 (8), 1640-1650, 2022 | 31 | 2022 |
| Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer PÖ Eser, RM Paranal, J Son, E Ivanova, Y Kuang, HM Haikala, C To, ... Science translational medicine 13 (609), eabb3738, 2021 | 14 | 2021 |
| Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance H Kimura, RM Paranal, N Nanda, LD Wood, JR Eshleman, RH Hruban, ... Elife 11, e71137, 2022 | 5 | 2022 |
| Somatic loss of ATM is a late event in pancreatic tumorigenesis RM Paranal, Z Jiang, D Hutchings, V Kryklyva, C Gauthier, K Fujikura, ... The Journal of Pathology 260 (4), 455-464, 2023 | 2 | 2023 |
| Switch to MET oncogene dependence as a novel mechanism of drug resistance in EGFR-mutant lung cancer PÖ Eser, RM Paranal, MJ Poitras, M Xu, S Wang, A Ogino, J Choi, ... Cancer Research 79 (13_Supplement), 1732-1732, 2019 | 2 | 2019 |
| P3. 02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma C Ambrogio, J Kohler, Z Zhou, H Wang, R Paranal, M Capelletti, ... Journal of Thoracic Oncology 12 (11), S2261, 2017 | 1 | 2017 |
| Understanding familial risk of pancreatic ductal adenocarcinoma RM Paranal, LD Wood, AP Klein, NJ Roberts Familial Cancer, 1-10, 2024 | | 2024 |
| Optimizing an in vitro toolbox to interrogate pancreatic tumorigenesis from a patient-derived intraductal papillary mucinous neoplasm sample RM Paranal, J Schlanz, MA Trujillo, NJ Roberts, LD Wood Cancer Research 83 (7_Supplement), 6511-6511, 2023 | | 2023 |
| Kinetics and thermodynamics of beta sheet formation and disaggregation RM Paranal, S Petty ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 247, 2014 | | 2014 |
